{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sinakos E"],"funding":["NCATS NIH HHS","NIDDK NIH HHS","NIEHS NIH HHS","NHLBI NIH HHS"],"pagination":["213-225"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9062842"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(3)"],"pubmed_abstract":["The prevalence of nonalcoholic fatty liver disease (NAFLD) is rapidly growing throughout the world. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is likely to become the leading cause of cirrhosis and etiology for liver transplantation in future decades in the Western World. Most patients with NAFLD have some components of metabolic syndrome, including obesity, insulin resistance, dyslipidemia, and hypertension. NAFLD encompasses a wide spectrum of liver damage, ranging from simple steatosis to NASH, that can progress to advanced liver disease, as well as hepatocellular carcinoma. Unfortunately, the options for the pharmacological treatment of NASH are still very limited. Nonetheless, several classes of therapies have shown promise, and are currently being evaluated i"],"journal":["Annals of gastroenterology"],"pubmed_title":["Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis."],"pmcid":["PMC9062842"],"funding_grant_id":["R01 DK121378","R01 DK124318","UL1 TR001442","P30 DK120515","R01 DK106419","U01 DK061734","P01 HL147835","P42 ES010337"],"pubmed_authors":["Liava C","Loomba R","Sinakos E"],"additional_accession":[]},"is_claimable":false,"name":"Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis.","description":"The prevalence of nonalcoholic fatty liver disease (NAFLD) is rapidly growing throughout the world. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is likely to become the leading cause of cirrhosis and etiology for liver transplantation in future decades in the Western World. Most patients with NAFLD have some components of metabolic syndrome, including obesity, insulin resistance, dyslipidemia, and hypertension. NAFLD encompasses a wide spectrum of liver damage, ranging from simple steatosis to NASH, that can progress to advanced liver disease, as well as hepatocellular carcinoma. Unfortunately, the options for the pharmacological treatment of NASH are still very limited. Nonetheless, several classes of therapies have shown promise, and are currently being evaluated i","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May-Jun","modification":"2025-04-22T05:51:04.873Z","creation":"2025-04-05T21:27:53.007Z"},"accession":"S-EPMC9062842","cross_references":{"pubmed":["35599922"],"doi":["10.20524/aog.2022.0704"]}}